GlassScriptPhysician profile
Yong Han
NPI 1679936660
$3,297.45
in general payments reported to CMS, 2019-2025
14 companies · $285 in 2025
The $285 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $140 · 2021: $431 · 2022: $323 · 2023: $1,001 · 2024: $1,119 · 2025: $285.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,404.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,404.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $886.36 | 2021-2024 | Eylea Hd, Eylea |
| Alimera Sciences, INC. | $793.15 | 2020-2024 | Yutiq, Iluvien |
| Apellis Pharmaceuticals, INC. | $357.26 | 2022-2024 | Syfovre |
| Genentech USA, INC. | $284.91 | 2023-2025 | Vabysmo |
| Astellas Pharma US INC | $272.37 | 2024-2025 | Izervay |
| Alcon Vision LLC | $188.68 | 2020-2025 | Rocklatan, Tryptyr, Eysuvis |
| Genentech, INC. | $131.13 | 2023 | Vabysmo |
| Abbvie INC. | $112.84 | 2023-2024 | |
| Mallinckrodt Hospital Products INC. | $64.26 | 2023-2024 | Acthar |
| Sandoz INC. | $59.74 | 2024 | Cimerli |
| Oyster Point Pharma, INC. | $56.56 | 2025 | Tyrvaya |
| Dentsply Sirona INC | $46.52 | 2025 | Implant Dentistry |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $22.02 | 2021 | |
| Bausch & Lomb Americas INC. | $21.65 | 2023 | Xipere |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yong Han listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.